An empty clinic waiting area with two chairs and a plant in morning light, for a report on a new study of transition regret

NewsroomTrans advocacyAnalysis

New JAMA Pediatrics Study Finds Transition Regret Is Rare

A new study asked people who began hormone therapy as youth how they feel about it now.

A new study in JAMA Pediatrics finds that transition regret is rare among people who began hormone therapy as teenagers. Researchers surveyed young people and young adults who had started hormone therapy as youth at a single multidisciplinary gender clinic in the United States. Among the 372 who completed the regret measure, 360—96.8%—said receiving hormone therapy “was the right decision.” Ten, or 2.7%, reported regret, and seven, or 1.9%, said it had harmed them.

The study, “Satisfaction, Regret, and Harm After Hormone Therapy in Youth From a Multidisciplinary Gender Clinic,” was published online on November 9, 2026. Its authors wrote that the results “provide support for existing standards of care rather than broad restrictions on youths’ access” to hormone therapy. That matters, because the fear of transition regret has carried much of the case for state bans on gender-affirming care for minors. For trans young people and the families who love them, this is evidence, not a verdict—and it’s worth reading closely for what it shows and what it can’t.

01

What the JAMA Pediatrics study measured

A stack of blank survey forms beside a pencil and glasses, standing for the surveys behind the transition regret study
Fig. 1The findings come from self-report surveys collected from 2023 to 2025.

The JAMA Pediatrics study has five authors. Laura Kuper, PhD, and Megan Ungerman, MD, are in the Department of Psychiatry at the University of Texas Southwestern Medical Center in Dallas. Bree Horrocks, PhD, is at Boston Children’s Hospital and Harvard Medical School. Diane Chen, PhD, is at Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine, and Ximena Lopez, MD, is in the Department of Pediatrics at the University of California, San Diego.

It’s a cohort study built on self-report surveys, collected from October 2023 to October 2025 from people who had received care at one multidisciplinary gender clinic. Erin in the Morning reports that the institutional review board at UT Southwestern approved the study, and it called the paper the largest transition regret study ever.

The paper counts 376 participants who began hormone therapy as youth. Four of them were missing regret scores, which is why the transition regret findings are reported for 372 people. On average, participants started hormone therapy at 16.0 years old. By the time they answered the survey, they ranged in age from 14 to 28.

They’d been on that path for very different lengths of time. Time since starting hormone therapy ranged from 1.2 months to 10.7 years, with an average of 4.9 years. That range is why some coverage describes the findings as reaching “up to 10 years” after treatment began.

The survey behind these transition regret findings asked about four things: whether people were satisfied with the decision, whether they felt transition regret, whether they believed hormone therapy had harmed them, and whether they were still receiving it.

02

The numbers: 96.8% satisfied, 2.7% reporting transition regret

The headline figures come straight from the paper. Of the 372 participants with regret scores, 360 said receiving hormone therapy was the right decision. Ten reported transition regret. Seven reported perceived harm.

The regret scores themselves were low across the group. The average score on the study’s regret scale was 4.3, and the median was 0, which means at least half of the participants reported no transition regret at all. The paper’s Key Points put it plainly: “satisfaction with HT was high and regret and harm were rare.”

Most participants were still on treatment. Of the 376, 311 (82.7%) were receiving hormone therapy when they were surveyed, and 65 (17.3%) weren’t. Stopping and regretting aren’t the same thing in this data: 65 people weren’t on hormone therapy at the time, while 10 reported regret.

Coverage of the transition regret findings has rounded those numbers in different ways. Erin in the Morning described rates of regret as “only about 3%,” and The Advocate, republishing a report by Them, described “a sample of nearly 400 people.” Bloom uses the paper’s own counts: 376 who began hormone therapy as youth, 372 with regret scores.

03

Age at the start of hormone therapy didn’t predict regret

One finding speaks directly to a question lawmakers and families often ask: were these young people too young to decide, and would early treatment lead to transition regret later? The researchers looked for a link between transition regret and the age at which someone started hormone therapy. They didn’t find one.

“Neither regret or harm nor current HT status was associated with age at HT initiation or prepubertal gender diversity,” the paper’s abstract says. In plain words, people who started younger weren’t more likely to report transition regret or harm. Nor were they more likely to have stopped treatment.

The same held for whether someone had been gender-diverse before puberty. The researchers tested that early history as a possible predictor, and in this group it didn’t predict transition regret, harm or stopping.

That’s one study, from one clinic. But it’s a direct answer, in a peer-reviewed journal, to a transition regret question often raised in arguments for waiting until adulthood.

04

Where transition regret was higher, and why that matters

The study doesn’t claim that regret never happens, and it would be dishonest to read it that way. It found two groups with higher transition regret scores.

The first was people who weren’t on hormone therapy when they were surveyed. Their regret scores averaged about 16 points higher than those of people still receiving it. The second was participants on the nonbinary spectrum, whose scores averaged about 6 points higher. The paper lists 47 participants, or 12.9%, as nonbinary, and counts 75, or 20.9%, on the nonbinary spectrum by a broader measure.

Bloom treats transgender, non-binary and gender-nonconforming as three distinct things, not one umbrella. A nonbinary person’s goals for their body may not match the path a clinic designed with binary transition in mind. This finding is a reason to listen more closely to nonbinary patients, not a reason to close the door on them.

The researchers point to another pressure on stopping. “Given recent increases in external barriers to accessing HT, rates of stopping treatment are likely increasing,” the study says, as quoted by Erin in the Morning. When insurance, law or distance pushes someone off treatment, stopping can reflect the barrier, not a change of heart.

The authors also urge humility. According to The Advocate’s report, they “caution against making assumptions about treatment satisfaction, regret, or harm.” That caution cuts both ways, and Bloom takes it seriously.

05

What a single-clinic survey can and can’t tell us

Every study has edges, and this one names its own. Any honest reading of transition regret data starts there. The Key Points describe “a single multidisciplinary clinic,” so the results describe that clinic’s patients and its model of care. A clinic with a different approach might see different results.

The findings are self-reported. That’s the right way to ask someone whether they regret a decision about their own body, but it also means the study measures what people were willing and able to say at one moment in time.

The cohort is also young. Participants were 14 to 28 when surveyed, and the average time since starting hormone therapy was 4.9 years. The study can speak to the first years after treatment, and in some cases a decade. It can’t speak to how someone will feel at 50, and it doesn’t pretend to.

Ten people reported transition regret, and seven reported harm. Numbers that small make it harder to find patterns among them, which is one more reason to treat this as strong evidence about the group, not a prediction for any single person.

06

How this fits the research on gender-affirming care

The authors don’t present their work on transition regret as the last word. They wrote that their findings “complement the literature documenting mental health benefits of HT.” They added that the results provide “further support for existing standards of care for transgender and gender-diverse youth.”

The Advocate’s report places the study alongside earlier research. It cites a 2022 study in JAMA Network Open that found trans youth with access to gender-affirming care “had better mental health outcomes” than those who were prevented from getting treatment. It also cites a “large-scale” 2021 study in the Journal of Adolescent Health that found “overwhelmingly positive effects” for trans youth.

Clinicians outside the study have said much the same. Scott Leibowitz, a child and adolescent psychiatrist on the board of WPATH, told The Washington Post that the study “adds to the growing evidence base that demonstrates individualized gender-affirming care can be beneficial for a young person.” Erin in the Morning reported his comment.

The word that matters there is individualized. The standards of care the study supports aren’t a conveyor belt. They’re a process of assessment and conversation, and the low rate of transition regret is, in part, a measure of that process working.

07

Why transition regret became a policy argument

The empty stone steps and columns of a statehouse at dusk, standing for how transition regret became an argument for bans
Fig. 2Bans on care for minors have often been argued on the fear of regret.

Fear of transition regret has done heavy lifting in statehouses. The Advocate notes that bans on gender-affirming care for minors have “passed into law in 27 U.S. states.” Its author wrote that the new findings “contradict the central argument used to justify bans on gender-affirming care for minors.”

The researchers made a narrower point in their own words. According to The Advocate, they wrote that the results “do not support efforts to categorically restrict or ban access to” hormone therapy for trans and gender-diverse youth. A study of transition regret can’t write a law. It can test the facts a law claims to rest on, and those facts deserve the same scrutiny the law’s supporters ask of the science.

Bloom has reported how those restrictions reach families. In New Hampshire, four trans teenage girls are asking a judge to pause a rule that, since October 13, has cut federal money out of Medicaid gender-affirming care for anyone under 18. In Colorado, voters this month approved Propositions 134 and 135, two citizen-initiated laws about trans youth.

Federal workers are in court too. They’ve asked a judge to block OPM’s exclusion of gender-affirming care from their health plans before it tightens in January. Each of these fights is about who decides: families and their doctors, or legislatures and agencies. This study adds evidence to that question, measured in the experiences of the young people themselves.

08

What families and young adults can take from this

Two mugs of tea and an open notebook on a kitchen table, for the section on what families can take from the transition regret study
Fig. 3Bring the study to the table, and to the people who provide care.

No study can make a decision for your family. But this one can help you ask better questions and push back on fear with facts.

  • Read the study yourself, or ask someone you trust to read it with you. The authors’ conclusions are short and clear.
  • Bring it to your clinician. Ask how they assess readiness, how they talk about goals and what happens if those goals change.
  • If you or your child is nonbinary, say so plainly and ask how care can fit your goals, not a template.
  • If treatment has been interrupted by insurance, law or distance, write down when and why. Stopping because of a barrier isn’t the same as transition regret.
  • Ask what the clinic does when someone does feel transition regret: what support exists, who provides it and how quickly.
  • Keep copies of records, prescriptions and insurance letters. Rules are changing quickly, and records protect you.

None of this guarantees an outcome. All of it puts the person receiving care back at the centre of the decision.

09

Regret is real, and so is care

Ten people in this study regret starting hormone therapy. Their experience is real, and they deserve care, respect and good medicine—not to be held up as a weapon against everyone else. No one should face transition regret alone, and no one should be made into a symbol of it. Three hundred and sixty people said the decision was right. Their experience is real too, and it’s the one most often left out of the argument.

Transition regret is worth studying honestly, and this study does. What it finds is that young people, given careful care, overwhelmingly know themselves. That shouldn’t be a radical finding. It should be the starting point.

If this news lands heavy today, you don’t have to carry it alone. Trans Lifeline answers at 877-565-8860, The Trevor Project at 1-866-488-7386, and the 988 Suicide and Crisis Lifeline by call or text at 988. Bloom’s crisis support page lists more help.

And if fear for a child, or grief over care already lost, is sitting with you, Faith in Bloom offers pastoral care with no condition attached.

10

What Bloom is doing

Bloom is a trans-led and disabled-led registered 501(c)(3) in Salem, Oregon. Our newsroom will keep reading the research on gender-affirming care at the source, including new studies of transition regret, report what it finds in plain words, and link the studies so you can read them yourself. You’ll find that coverage in the Trans Advocacy newsroom.

We’re also following the fights over records and access, including the Justice Department subpoenas for trans patients’ records and the state laws written to protect them. If your family is weighing whether to stay where you are, start with Bloom’s Trans Relocation page.

11

Frequently Asked Questions

Among 372 people who began hormone therapy as youth and completed the regret measure, 360 (96.8%) said it was the right decision, 10 (2.7%) reported regret and 7 (1.9%) reported perceived harm. The study was published online on November 9, 2026.

It included 376 people who started hormone therapy as youth at a single multidisciplinary gender clinic in the United States. They started treatment at an average age of 16.0 and were 14 to 28 years old when surveyed between October 2023 and October 2025.

No. The paper reports that neither regret or harm nor current treatment status was associated with age at the start of hormone therapy or with gender diversity before puberty.

Yes. Regret scores were higher among people who weren’t on hormone therapy when surveyed and among people on the nonbinary spectrum. The authors caution against making assumptions about satisfaction, regret or harm.

No. In the study, 65 participants weren’t on hormone therapy when surveyed, while 10 reported transition regret. The researchers wrote that rising external barriers to care are likely increasing rates of stopping treatment.

It’s a cohort study of self-report surveys from one clinic, and participants were 28 or younger. It describes the first years after treatment, up to about a decade for some participants, not lifelong outcomes.

The authors wrote that the results support existing standards of care “rather than broad restrictions on youths’ access” to hormone therapy. The study doesn’t change any law, but it tests the claim about regret that many bans rest on.

Trans Lifeline answers at 877-565-8860, The Trevor Project at 1-866-488-7386, and the 988 Suicide and Crisis Lifeline by call or text at 988. Bloom’s crisis support page lists more.

Sovereignty over Servitude. 🌸